Company / Operating Cash Flow per Share
CRISPR Therapeutics AG Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$4.02
FY2025
5-year range
-$6.44 / $7.29
FY2021-FY2025
Trend
-125.6%
vs FY2024
Sector context
#185 of 210
Health Care
What the data says
CRISPR Therapeutics AG's operating cash flow per share of $-4.02 is lower than 88% of companies in the Health Care sector (FY2025). Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $-9.56 in FY2016 to $7.29 in FY2021.
Based on SEC 10-K filings.
-4.02 in FY2025.
Declined from $-3.32 to $-4.02 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 210This company -$4.02 Sector average $5.30
▼
-175.9% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 125.6% year-over-year.
- Ranks #185 out of 210 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2021.
- Lowest operating cash flow per share in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$4.02 | -125.6% |
| FY2024 | -$1.78 | +46.2% |
| FY2023 | -$3.32 | +48.5% |
| FY2022 | -$6.44 | -188.3% |
| FY2021 | $7.29 | +285.9% |
| FY2020 | -$3.92 | -458.8% |
| FY2019 | $1.09 | +146.1% |
| FY2018 | -$2.37 | -34.3% |
| FY2017 | -$1.76 | +81.5% |
| FY2016 | -$9.56 | -181.1% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026